David Meline Biography and Net Worth

CFO of Moderna

As Chief Financial Officer, David Meline oversees financial, business development and business services functions at Moderna.

Mr. Meline previously served as Chief Financial Officer and EVP at Amgen from 2014 through 2019. At Amgen, he was responsible for all finance, information systems and global business services activities across 100 countries. In this role, Mr. Meline led enterprise-wide transformation while increasing growth and productivity and reducing development cycle time. Prior to Amgen, Mr. Meline spent six years at 3M Company, where he most recently served as CFO and Senior Vice President and was responsible for all 3M financial activities across 70 countries of operation. Previously, Mr. Meline held numerous leadership positions at General Motors, including Vice President and CFO for GM North America. During his tenure at GM, Mr. Meline lived and worked on five continents.

Mr. Meline received his Master of Business Administration in finance from the University of Chicago, his Master of Science in economics from the London School of Economics and his Bachelor of Science in mechanical engineering from Iowa State University.

What is David W. Meline's net worth?: The estimated net worth of David W. Meline is at least $1.58 million as of March 6th, 2024. Mr. Meline owns 40,000 shares of Moderna stock worth more than $1,575,600 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Meline may own. Learn More about David W. Meline's net worth.
How do I contact David W. Meline?: The corporate mailing address for Mr. Meline and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected]. Learn More on David W. Meline's contact information.
Has David W. Meline been buying or selling shares of Moderna?: David W. Meline has not been actively trading shares of Moderna during the last ninety days. Most recently, David W. Meline sold 164 shares of the business's stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $173.66, for a transaction totalling $28,480.24. Following the completion of the sale, the chief financial officer now directly owns 2,857 shares of the company's stock, valued at $496,146.62. Learn More on David W. Meline's trading history.
Who are Moderna's active insiders?: Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (Chief Executive Officer), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.
Are insiders buying or selling shares of Moderna?: During the last year, insiders at the sold shares 49 times. They sold a total of 647,813 shares worth more than $81,384,380.50. The most recent insider tranaction occured on December, 9th when insider Shannon Thyme Klinger sold 529 shares worth more than $23,635.72. Insiders at Moderna own 15.7% of the company. Learn More about insider trades at Moderna.
Information on this page was last updated on 12/9/2024.

David W. Meline Insider Trading History at Moderna

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/10/2022	Sell	164	$173.66	$28,480.24	2,857
5/10/2022	Sell	156	$133.71	$20,858.76	2,583
2/10/2022	Sell	619	$158.89	$98,352.91

David W. Meline Buying and Selling Activity at Moderna

Moderna Company Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $39.39

$39.12

$40.83

50 Day Range

MA: $46.43

$36.85

$57.73

2 Week Range

Now: $39.39

$35.80

$170.47

Volume

35,464,590 shs

Average Volume

5,143,892 shs

Market Capitalization

$15.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Most People Are Dead Wrong.

From Brownstone Research | Ad

Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.